Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Replimune Group Inc.

    NASDAQ: REPL · Real-Time Price · USD
    5.32
    -0.24 (-4.32%)
    At close: Aug 18, 2025, 3:59 PM
    5.36
    0.75%
    After-hours: Aug 18, 2025, 07:38 PM EDT
    -4.32%
    Bid 5.28
    Market Cap 415.26M
    Revenue (ttm) n/a
    Net Income (ttm) -247.3M
    EPS (ttm) -3.24
    PE Ratio (ttm) -1.64
    Forward PE -1.82
    Analyst Hold
    Ask 5.45
    Volume 2,381,845
    Avg. Volume (20D) 9,032,640
    Open 5.42
    Previous Close 5.56
    Day's Range 5.18 - 5.48
    52-Week Range 2.68 - 17.00
    Beta 0.67

    About REPL

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol REPL
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for REPL stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Next Earnings Release

    Replimune Group Inc. is scheduled to release its earnings on Nov 11, 2025, before market opens.
    Analysts project revenue of ... Unlock content with Pro Subscription
    1 week ago
    +10.68%
    Replimune shares are trading higher, reversing aft... Unlock content with Pro Subscription
    2 weeks ago
    +101.33%
    Shares of several biotechnology stocks are trading higher amid Vinay Prasad's departure as director of the FDA's Center for Biologics Evaluation and Research.
    news image

    6 days ago · businesswire.com

    NASDAQ: REPL: Kessler Topaz Meltzer & Check, LLP Announces the Filing of a Securities Class Action Lawsuit Against Replimune Group, Inc.

    RADNOR, Pa.--(BUSINESS WIRE)-- #classaction--The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Replimune...

    news image

    1 week ago · fool.com

    Replimune (REPL) Q1 Loss Widens 61%

    Replimune (REPL) Q1 Loss Widens 61%

    news image

    1 week ago · seekingalpha.com

    Replimune Group: The Prospects For FDA Approval After Rejection

    Replimune Group's RP1 oncolytic virus therapy faced an FDA rejection, raising concerns about the platform's viability in refractory melanoma. The company's pipeline is centered on RP1, making the rece...

    news image

    2 weeks ago · benzinga.com

    Why Is Replimune Stock Trading Lower On Monday?

    On Monday, Replimune Group Inc. REPL is reeling after the FDA unexpectedly rejected its skin cancer treatment, triggering a stock plunge and a wave of investor outrage.

    news image

    3 weeks ago · businesswire.com

    REPL LEGAL UPDATE: Replimune Group, Inc. Sued after FDA Response Letter -- Investors with Losses are Notified to Contact BFA Law before September 22 Class Action Deadline

    NEW YORK--(BUSINESS WIRE)---- $REPL #Attorney--Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Replimune Group, Inc. (NASDAQ: REPL) and certain o...

    news image

    3 weeks ago · businesswire.com

    REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with the Schall Law Firm

    LOS ANGELES--(BUSINESS WIRE)---- $REPL--REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with the Schall Law Firm.

    news image

    3 weeks ago · businesswire.com

    EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit on Behalf of Replimune Group, Inc. Investors – REPL

    NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of Replimune Group, Inc. (NASDAQ: ...

    Add to Watchlist